Document Detail

Efficacy and safety of cilazapril, a new angiotensin-converting enzyme inhibitor.
MedLine Citation:
PMID:  2970856     Owner:  NLM     Status:  MEDLINE    
Cilazapril (CIL), a new angiotensin-converting enzyme inhibitor, was evaluated for 16 weeks in 29 patients with mild to moderate essential hypertension (diastolic pressure 95 mm Hg to 115 mm Hg). Twenty-four patients (83%) normalized their blood pressure (BP) (diastolic pressure less than 90 mm Hg), 11 with low-dose CIL, six with high-dose CIL, one with high-dose CIL plus low-dose thiazide, and six with high-dose CIL and high-dose thiazide. Three withdrew because of side effects (fatigue, bloating, and polyuria). Statistically significant reductions in sitting and standing systolic and diastolic pressures occurred at 8 and 16 weeks on CIL. There was no change in standing or sitting heart rate, white blood cell count, creatinine clearance, urine protein levels. This is the first long-term data on this new converting enzyme inhibitor in human beings.
R C Goldszer; R Rodriguez; H S Solomon
Related Documents :
19092146 - Modulation of blood pressure by central melanocortinergic pathways.
16758526 - Twelve-year blood pressure dynamics in adults in ljubljana area, slovenia: contribution...
24250976 - Administration of remifentanil in establishing a more stable post-anesthesia cardiovasc...
17309946 - Effect of spironolactone on blood pressure in subjects with resistant hypertension.
8144786 - Filling patterns in left ventricular hypertrophy: a combined acoustic quantification an...
11688366 - Prospects for the use of antioxidant therapy in hypertension.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of hypertension     Volume:  1     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  1988 Jul 
Date Detail:
Created Date:  1988-10-19     Completed Date:  1988-10-19     Revised Date:  2009-02-24    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  300S-302S     Citation Subset:  IM    
Department of Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aldosterone / blood,  urine
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Blood Pressure
Drug Therapy, Combination
Hypertension / blood,  drug therapy*,  physiopathology
Pyridazines / adverse effects,  standards,  therapeutic use*
Renin / blood
Sodium Chloride Symporter Inhibitors / therapeutic use
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Benzothiadiazines; 0/Diuretics; 0/Pyridazines; 0/Sodium Chloride Symporter Inhibitors; 52-39-1/Aldosterone; 92077-78-6/Cilazapril; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of fosenopril, a once-daily angiotensin-converting enzyme inhibitor, on resting and exercise...
Next Document:  Prevention of hypertension is associated with reduced susceptibility to histamine-induced arrhythmia...